Head and neck cancer (HNC) will affect more than an estimated 55,000 individuals in the US in 2014, the vast majority of these being squamous cell carcinoma (SCC), with 12,000 estimated deaths.
easier for patients to tolerate, have been studied. 14, 15 Results of several phase II and III trials testing cetuximab as part of an intensified treatment approach for patients with SCCHN, whether as an addition to induction chemotherapy (IC) or to the concurrent CRT, have been published in recent years. The best known of these trials is a phase III study conducted by
Bonner and colleagues that demonstrated that cetuximab in combination with radiotherapy also improves survival compared with radiation alone for patients with SCCHN. 16, 17 In this trial, 424 patients with stage III-IV SCC of the oropharynx, hypopharynx, or larynx were randomized to radiotherapy with or without cetuximab. The original publication reported that after a median follow-up of 4.5 years, a 10 % absolute overall survival (OS) benefit was observed in the concurrent cetuximab arm (45 % versus 55 %). Local-regional control was also significantly better with cetuximab (47 % versus 34 %). Of note, the patients who benefitted the most from receiving cetuximab were also treated with a concomitant boost radiation course, an accelerated fractionation approach that has been shown in a phase III randomized trial (RTOG 9003) to effect significantly improved local-regional control compared with the standard once-daily fractionation for locally advanced HNC. 18 Moreover, the subgroup analysis favored radiotherapy alone in patients with a Karnofsky Performance Status (KPS) 48 Two hundred and seventy patients were enrolled before the study was closed early at interim analysis. Median OS was 6 months in patients who were treated with docetaxel alone versus 7.3 months in patients who received the combination treatment.
An unplanned analysis showed improved survival in patients younger than 65 years who received gefitinib (median survival 7.6 versus 5.2 months; p=0.04). Except for grade 3-4 diarrhea, which was more common with docetaxel/gefitinib, the grade 3-4 toxicities were comparable between the two arms.
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